Open an account

Moderna

MRNA · NASDAQ

$242.08+$15.19 (+6.69%)TodayMarket closed ·
Prev close $226.89

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The company is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). The company also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. The company has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).

Employees
4,700
Headquarters
Cambridge, Massachusetts
Listed
Dec 7, 2018
Sector
Health Care
Industry
Biotechnology
Website
modernatx.com

MRNA key statistics

Market cap
90.58B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
18.61M
Volume
12.31M
Open price
$226.03
High today
$243.98
Low today
$216.65
52 Week high
$242.29
52 Week low
$22.28

Moderna (MRNA) at a glance

As of Oct 20, 2026, Moderna (MRNA) shares are priced at $242.08, giving the company a market cap of 90.58B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $216.65 and $243.98. The current price is 11.7% above the day's low and 0.8% below its high.

Volume so far is 12.31M shares, below the average of 18.61M shares a day.

Over the past year Moderna has ranged from $22.28 to $242.29, and now sits 100% of the way up that range.

Moderna met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$1.97 per share against an estimate of -$2.12.

The average analyst price target is $121.15, 50.0% below the current price, from 19 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

16%of 19 analyst ratings say Buy
  • Buy15.8%
  • Hold57.9%
  • Sell26.3%
Price target · 22 analystsAvg $121.15
Low
$40.40
Now
$242.08
High
$178.50

MRNA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 39.1% on average.

  1. Q3 FY24: reported $0.03 per share against an estimate of -$1.95
  2. Q4 FY24: reported -$2.91 per share against an estimate of -$2.74
  3. Q1 FY25: reported -$2.52 per share against an estimate of -$3.20
  4. Q2 FY25: reported -$2.13 per share against an estimate of -$3.03
  5. Q3 FY25: reported -$0.51 per share against an estimate of -$2.15
  6. Q4 FY25: reported -$2.11 per share against an estimate of -$2.70
  7. Q1 FY26: reported -$3.40 per share against an estimate of -$4.04
  8. Q2 FY26: reported -$1.97 per share against an estimate of -$2.12

MRNA news

  • Dylan Berman

    What's Going On With Moderna Stock Monday?

  • Piero Cingari

    Nasdaq 100 Slides As Micron, SanDisk, CoreWeave Sink: Stock Market Today

  • Erica Kollmann

    Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks

  • Press releaseGlobe Newswire

    AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Namrata Sen

    Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’

  • Ananya Gairola

    Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'

Similar companies

Companies in the same industry as Moderna

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.